Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page
- Check5 days agoChange DetectedThe record history shows an update to recruitment status, indicating the trial is active but not currently enrolling participants. This signals that enrollment is not open at this time.SummaryDifference0.1%

- Check12 days agoChange DetectedThe page's revision version was updated from v3.6.5 to v3.6.6, indicating a minor system update to the record history.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedA new revision entry (v3.6.5) has been added to the history, indicating a recent update to the page. The previous revision (v3.6.4) is listed under deletions, suggesting it is no longer part of the current change set.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision: v3.6.4 replaced v3.6.3 in the page history, indicating a new version of the record was published.SummaryDifference0.1%

- Check55 days agoChange DetectedOn 2026-07-13, a Study Status entry was added to the record history to reflect the current status of the trial. On 2026-07-10, a numeric value 28 was added in the history, and a prior deletion on 2026-04-07 removed an earlier item from the history.SummaryDifference0.3%

- Check70 days agoChange DetectedThe history shows a new revision entry, Revision: v3.6.3, added to replace the previous Revision: v3.6.2.SummaryDifference0.1%

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.